Vaidya Sane

Which are the latest news on Vaidya Sane?

Why is Vaidya Sane Ayurved Laboratories Ltd falling/rising?

As of 05-Sep, Vaidya Sane Ayurved Laboratories Ltd's stock price has risen slightly to 160.50, but it faces significant declines over various periods, including a 43.60% drop year-to-date. Despite today's minor increase, the stock shows a bearish trend with low profitability and reduced investor interest.

As of 05-Sep, Vaidya Sane Ayurved Laboratories Ltd is experiencing a slight rise in its stock price, currently at 160.50, with a change of 0.2 (0.12%) upwards. However, this minor increase occurs against a backdrop of significant declines in the stock's performance over various time periods. Over the past week, the stock has fallen by 5.28%, and in the last month, it has decreased by 16.36%. Year-to-date, the stock is down 43.60%, and it has lost 46.14% over the past year. <BR><BR>Despite today's performance showing an outperformance against its sector by 0.57%, the stock is trading below its moving averages across all time frames, indicating a bearish trend. Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 64.29% compared to the 5-day average. <BR><BR>The company's financial health presents mixed signals; while it is net-debt free, it suffers from poor management efficiency, reflected in a low return on equity (ROE) of 7.89%. The recent flat results, where non-operating income constitutes a significant portion of profit before tax, further highlight concerns regarding profitability. <BR><BR>Overall, while there is a slight uptick in the stock price today, the broader context of declining performance metrics, low profitability, and reduced investor interest suggests that the stock is still facing significant challenges.

Who are in the management team of Vaidya Sane?

The management team of Vaidya Sane includes Rohit Madhav Sane (Managing Director & CEO), Vidyut Bipin Ghag (Whole-time Director), and three Independent Directors: Ratnakar Venkappa Rai, Sushrut Raghavendra Dambal, and Mahesh P. Kshirsagar, along with Abhishek Ajay Deshpande as Company Secretary & Compliance Officer.

The management team of Vaidya Sane includes the following members:<BR><BR>1. **Rohit Madhav Sane** - Managing Director & CEO<BR>2. **Vidyut Bipin Ghag** - Whole-time Director<BR>3. **Ratnakar Venkappa Rai** - Independent Director<BR>4. **Sushrut Raghavendra Dambal** - Independent Director<BR>5. **Mahesh P. Kshirsagar** - Independent Director<BR>6. **Abhishek Ajay Deshpande** - Company Secretary & Compliance Officer<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

What does Vaidya Sane do?

Vaidya Sane Ayurved Laboratories Ltd is a micro-cap company in the hospital industry, reporting net sales of ₹5,110 Cr and a net profit of ₹235 Cr for September 2023. Key metrics include a P/E ratio of 36.00 and a market cap of ₹178 Cr.

Overview: <BR>Vaidya Sane Ayurved Laboratories Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was originally incorporated in 1999 as a Private Limited Company and later converted into a Public Limited Company. The latest quarterly results reported net sales and net profit for September 2023.<BR><BR>Financial Snapshot: <BR>Net Sales: 5,110 Cr (Quarterly Results - Sep 2023) <BR>Net Profit: 235 Cr (Quarterly Results - Sep 2023) <BR>Market Cap: INR 178 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 36.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.24 <BR>Return on Equity: 6.13% <BR>Price to Book: 2.22 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Vaidya Sane?

Vaidya Sane's peers include Chandan Healthcare, Aprameya Engineering, Lotus Eye Hospital, Nephro Care, KHFM Hospitality, Aashka Hospitals, Abate As Industries, Asarfi Hospital, and Fortis Malar. Vaidya Sane has average management risk and growth, with a 1-year return of -40.27%, worse than Nephro Care's -34.31%.

Peers: The peers of Vaidya Sane are Chandan Healthca, Aprameya Enginee, Lotus Eye Hospit, Nephro Care, KHFM Hospitality, Aashka Hospitals, Abate As Indust, Asarfi Hospital, and Fortis Malar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Chandan Healthca and Nephro Care, while Average management risk is found at Vaidya Sane and Asarfi Hospital. Below Average management risk is noted at Lotus Eye Hospit, KHFM Hospitality, Aashka Hospitals, Abate As Indust, and Fortis Malar. For growth, Excellent growth is seen at Chandan Healthca and Nephro Care, Average growth at Vaidya Sane, and Below Average growth at Aprameya Enginee, Lotus Eye Hospit, KHFM Hospitality, Aashka Hospitals, and Abate As Indust. Good capital structure is present at Chandan Healthca, Aprameya Enginee, Nephro Care, and Asarfi Hospital, while Vaidya Sane, Lotus Eye Hospit, and the rest have a Good capital structure.<BR><BR>Return Snapshot: Nephro Care has the highest 1-year return at -34.31%, while Vaidya Sane has the lowest at -40.27%, indicating that Vaidya Sane's return is worse than Nephro Care's. Additionally, KHFM Hospitality, Aashka Hospitals, Abate As Indust, and Fortis Malar all have negative six-month returns.

How big is Vaidya Sane?

As of 31st August, Vaidya Sane Ayurved Laboratories Ltd has a market capitalization of 178.00 Cr, with recent net sales of 19585.66 Cr and a net profit of 1448.51 Cr. Shareholder's funds are 62.54 Cr and total assets are valued at 76.71 Cr as of March 2025.

As of 31st August, Vaidya Sane Ayurved Laboratories Ltd has a market capitalization of 178.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 19585.66 Cr and a Net Profit of 1448.51 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 62.54 Cr and Total Assets valued at 76.71 Cr.

Should I buy, sell or hold Vaidya Sane Ayurved Laboratories Ltd?

Is Vaidya Sane overvalued or undervalued?

As of November 6, 2025, Vaidya Sane is considered very expensive and overvalued with a PE ratio of 48.20 and an EV to EBITDA of 26.00, significantly higher than its peers like Sun Pharma and Cipla, despite a strong year-to-date return of 90.47%.

As of 6 November 2025, the valuation grade for Vaidya Sane has moved from expensive to very expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 48.20, an EV to EBITDA of 26.00, and a PEG ratio of 0.11, which indicates a significant premium compared to its peers.<BR><BR>In comparison to its industry peers, Sun Pharma has a PE ratio of 35.02 and an EV to EBITDA of 10.54, while Cipla is valued more attractively with a PE ratio of 22.27 and an EV to EBITDA of 5.53. Despite Vaidya Sane's strong year-to-date return of 90.47%, which outperforms the Sensex's 7.89%, the current valuation metrics suggest that the stock is not justified at its price level.

How has been the historical performance of Vaidya Sane?

Vaidya Sane has shown significant growth from Mar'22 to Mar'25, with net sales rising to 89.85 Cr despite a decline from the previous year, and profit before tax increasing to 9.90 Cr. The company improved its operating profit and earnings per share, indicating a strong upward trend in revenue and profitability.

Answer:<BR>The historical performance of Vaidya Sane shows a significant growth trajectory, particularly from fiscal year Mar'22 to Mar'25.<BR><BR>Breakdown:<BR>Vaidya Sane's net sales increased from zero in Mar'22 to 89.85 Cr in Mar'25, although there was a decline from 99.33 Cr in Mar'24. Total operating income followed a similar trend, rising from zero to 89.85 Cr, with a slight decrease from the previous year. The company managed to reduce its total expenditure from 94.83 Cr in Mar'24 to 76.34 Cr in Mar'25, contributing to an operating profit (PBDIT) of 15.37 Cr in Mar'25, up from 6.25 Cr in Mar'24. Profit before tax also saw a notable increase, reaching 9.90 Cr in Mar'25 compared to 2.86 Cr in Mar'24, while profit after tax rose to 7.15 Cr from 1.99 Cr. The earnings per share (EPS) improved significantly from 1.88 in Mar'24 to 6.79 in Mar'25. On the balance sheet, total liabilities increased from 54.81 Cr in Mar'23 to 70.82 Cr in Mar'24, with total assets also rising to 70.82 Cr in Mar'24. Cash flow from financing activities showed a strong inflow of 14.00 Cr in Mar'24, contributing to a closing cash balance of 13.00 Cr, up from 1.00 Cr in the previous year. Overall, Vaidya Sane has demonstrated a robust growth pattern in revenue and profitability over the past few years.

Who are the top shareholders of the Vaidya Sane?

The top shareholders of Vaidya Sane are led by promoter Rohit Madhav Sane, who holds 66.29% of the shares, followed by public shareholder Virtuous Capital Limited with 4.17%. Individual investors own 21.94%, with no mutual funds or foreign institutional investors currently involved.

The top shareholders of Vaidya Sane include the promoters, with Rohit Madhav Sane holding the largest share at 66.29%. The highest public shareholder is Virtuous Capital Limited, which holds 4.17%. Additionally, individual investors collectively own 21.94% of the company. Notably, there are no mutual funds or foreign institutional investors currently holding shares in Vaidya Sane.

What is the technical trend for Vaidya Sane?

As of June 3, 2025, the market trend is mildly bullish, supported by a bullish weekly MACD and Bollinger Bands, although caution is advised due to mixed signals from the monthly MACD and daily moving averages.

As of 3 June 2025, the technical trend has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive outlook, while the monthly MACD is mildly bearish, indicating some caution. The Bollinger Bands on the weekly are bullish, reinforcing the upward momentum. However, the daily moving averages are mildly bearish, suggesting short-term weakness. The Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames, and the On-Balance Volume (OBV) is also mildly bullish, reflecting positive accumulation. Overall, the current stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite some mixed signals from other indicators.

When is the next results date for Vaidya Sane?

No Upcoming Board Meetings

Has Vaidya Sane declared dividend?

Yes, Vaidya Sane Ayurved Laboratories Ltd has declared a 2% dividend, amounting to ₹0.20 per share, with an ex-date of September 5, 2023. However, total returns over various periods have shown negative performance, with minimal contributions from dividends.

Yes, Vaidya Sane Ayurved Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: ₹0.20<BR>- Ex-date: 05 Sep 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -3.24%, the dividend return was 0%, resulting in a total return of -3.24%.<BR><BR>Over the past year, the price return was -1.3%, the dividend return was 0%, leading to a total return of -1.3%.<BR><BR>In the 2-year period, the price return was -41.09%, the dividend return was 0.08%, resulting in a total return of -41.01%.<BR><BR>For the 3-year period, the price return was -18.02%, the dividend return was 0.26%, which led to a total return of -17.76%.<BR><BR>In the 4-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>Over the last 5 years, both the price return and dividend return were 0%, leading to a total return of 0.0%.<BR><BR>Overall, while Vaidya Sane has declared a dividend, the total returns over various periods indicate a trend of negative performance, particularly in the longer term, with minimal contributions from dividends.